Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine. - Wikidata - wikimedia - TriplyDB

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

http://www.wikidata.org/entity/Q37459147

about

Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.Synthesis and biological characterization of protease-activated prodrugs of doxazolidine Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2.Leveraging Colloidal Aggregation for Drug-Rich Nanoparticle Formulations.Undesired versus designed enzymatic cleavage of linkers for liver targeting The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer.

P2860

Q33916086-BF00FA8B-E388-4C51-B303-CBB6B9D5A4A7 Q34572507-B3B97138-8FA7-4B00-B360-F3A3D3991993 Q35569028-1C892989-B9D1-455E-8D6C-5ECF1AF8DA92 Q36206886-0D40CE03-5E7C-4DBA-B1DD-4D3D6068CD20 Q39200965-544FF855-6E6D-41B4-860A-EFF718D7FAD2 Q40124208-E8ED8F45-7B5E-42AD-A7C8-69C4434AF510 Q41303888-96C832EB-F666-495C-ABB9-363C308829D9 Q42126116-A7667390-B645-4B4D-AEA4-70ADC45CE443 Q52719672-8453FF29-C47E-44E8-9EE3-382952B08F86

P2860

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

http://www.wikidata.org/entity/Q37459147

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@en

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@nl

type

label

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@en

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@nl

prefLabel

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@en

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@nl

P1433

Q37459147-E68852E9-6054-40CB-9FF3-912F75FC4E3F

P1476

Q37459147-C898F630-38C7-4CDE-A591-7A25D7D966C2

P2093

Q37459147-218C7A20-EE69-4ACC-8877-2B5366D46C5B

Q37459147-26FAD81B-E15E-4E05-9A75-AF82918DD5C9

Q37459147-3E08BEC0-FADA-4E1B-85E0-911C96BF07DD

Q37459147-558AAF40-419B-494C-A490-CF3B379012F7

Q37459147-5E2A3E9E-EA8E-471A-BB94-7CBE5E2A787D

Q37459147-6A572E2C-369A-4CB6-AAAC-16C048B01ED0

Q37459147-91793FEB-E6D2-42AB-8FFC-BBBCD3D2A8CB

Q37459147-B929925C-DDF5-4D76-BB12-777A5AEE8FBA

Q37459147-F31523B1-A6BE-4112-B232-C88F87FA13F0

P2860

Q37459147-029FE0A5-5861-4135-ADD1-1B4BE6657B40

Q37459147-0C684E59-30DC-4E9E-9EBB-7EBA728D2A3B

Q37459147-1B1976A1-B485-4FD6-B25F-78B9D61E9DC7

Q37459147-2140CBAD-1132-4C92-B820-69958203BC2F

Q37459147-26773C67-716F-48CA-B7DB-990BC7E981D1

Q37459147-27F53DFC-3177-4D69-BE4F-26F9CC3B748E

Q37459147-29F77CE5-B5FA-4B7C-8519-5C3C0E37E5F3

Q37459147-31D1F641-C874-488A-AB6E-A93C3A41A691

Q37459147-36DB6164-7A41-495C-8081-8CB734C32B4A

Q37459147-3E4FD12F-A88F-4002-8BD8-458E21836ED5

P304

Q37459147-AAE38ACF-7B57-472E-B031-A1FA4BF93639

P31

Q37459147-18D014E2-AB61-43B3-B4AB-91577FECE961

P356

Q37459147-18E7D6F6-2F24-4499-943D-0DBBC9428328

P407

Q37459147-AD7A920B-DE37-40F1-B640-8E6A62CA954E

P433

Q37459147-88A8F39B-B7DF-4469-8E92-5B744D6BA81C

P478

Q37459147-CB7B40D7-8D8E-4D51-8153-146CE534A470

P577

Q37459147-77225E66-6197-4866-A75A-85997D21F46D

P5875

Q37459147-DE03AAA7-A415-4056-A5D4-AE34CE668420

P698

Q37459147-53E8E709-C982-46E5-B517-55209C7D1EBB

P932

Q37459147-5014A850-2896-4D22-A3C4-9EB88B106E03

P356

P1433

Journal of Medicinal Chemistry

P1476

Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.

@en

P2093

Benjamin L Barthel

http://www.w3.org/2001/XMLSchema#string

Christopher D Coldren

http://www.w3.org/2001/XMLSchema#string

Daniel C F Chan

http://www.w3.org/2001/XMLSchema#string

Daniel L Rudnicki

http://www.w3.org/2001/XMLSchema#string

Gary G Koch

http://www.w3.org/2001/XMLSchema#string

Hengrui Sun

http://www.w3.org/2001/XMLSchema#string

Margaret Polinkovsky

http://www.w3.org/2001/XMLSchema#string

Tad H Koch

http://www.w3.org/2001/XMLSchema#string

Zhiyong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Suppressive effect of superoxide dismutase on adriamycin nephropathy

Purification, molecular cloning, and functional expression of inducible liver acylcarnitine hydrolase in C57BL/6 mouse, belonging to the carboxylesterase multigene family

Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis.

Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.

Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.

Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a n

P304

7678-7688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM900694Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26697960

http://www.w3.org/2001/XMLSchema#string

P698

19634903

http://www.w3.org/2001/XMLSchema#string

P932

2788667

http://www.w3.org/2001/XMLSchema#string